← Back to Search

Photothermal Treatment

577-nm PASCAL laser for Macular Telangiectasia

N/A
Waitlist Available
Research Sponsored by The Lowy Medical Research Institute Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial is testing a special laser treatment that uses low heat to help heal the eyes of patients with Macular Telangiectasia Type 2. The goal is to see if this gentle laser can improve their condition without causing damage. Low level laser therapy (LLLT) is a form of phototherapy that has been used successfully to induce wound healing in nonhealing defects and other types of wounds.

Eligible Conditions
  • Macular Telangiectasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary study objectives
Change from baseline cone density as measured by confocal adaptive optics (AOSLO)
Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT)
Development or extension post therapy of areas of deficiency in cones as measured by AOSLO

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Subthreshold Photothermal TherapyExperimental Treatment1 Intervention
Group II: ShamPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
577-nm PASCAL laser
2018
N/A
~10

Find a Location

Who is running the clinical trial?

The Lowy Medical Research Institute LimitedLead Sponsor
7 Previous Clinical Trials
417 Total Patients Enrolled
~1 spots leftby Oct 2025